Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiopharmaceuticals for bone malignancy therapy

H L Atkins1, S C Srivastava

  • 1Medical Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA.

Journal of Nuclear Medicine Technology
|May 30, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of Conventional and Microwave Sintered Iron Ore Preform.

Materials (Basel, Switzerland)·2022
Same author

Cognitive change and neuroimaging following immunoablative therapy and hematopoietic stem cell transplantation in multiple sclerosis: A pilot study.

Multiple sclerosis and related disorders·2015
Same author

Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.

Blood cancer journal·2014
Same author

Production of actinomycin-D by the mutant of a new isolate of Streptomyces sindenensis.

Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]·2013
Same author

Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.

Blood cancer journal·2013
Same author

Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy.

Leukemia·2011
Same journal

<sup>18</sup>F-NaF PET/CT Versus <sup>18</sup>F-FDG PET/CT for Baseline Mapping in Ollier Disease: A Pediatric Case.

Journal of nuclear medicine technology·2026
Same journal

Incidental Detection of Aggressive HER2-Positive Breast Cancer on <sup>99m</sup>Tc-Sestamibi Parathyroid Scintigraphy.

Journal of nuclear medicine technology·2026
Same journal

Structured Educational Tours in Hospital-Based Radiopharmaceutical Production: Balancing Safety and Learning.

Journal of nuclear medicine technology·2026
Same journal

Development of a Phantom for Evaluating Image Quality and Partial-Volume Effects in Hot and Cold Regions in Small-Animal SPECT and PET.

Journal of nuclear medicine technology·2026
Same journal

Nonuniformity in a Certified <sup>68</sup>Ge PET Cylinder Phantom: Implications for Normalization Quality Assurance.

Journal of nuclear medicine technology·2026
Same journal

Reducing Formation of Suspected Tracer Microemboli During Preparation of <sup>99m</sup>Tc-Tagged Heat-Damaged Red Blood Cells.

Journal of nuclear medicine technology·2026
See all related articles

Radionuclide bone therapy agents offer pain relief for bone metastases and may be used with surgery or radiation. This review covers current and future agents for bone therapy.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiopharmaceutical Therapy

Background:

  • Bone metastases are a common and painful complication of various cancers.
  • Radionuclide bone-seeking agents offer a targeted approach to palliate pain from bone metastases.
  • The field is evolving with new agents under investigation.

Purpose of the Study:

  • To review currently available radionuclide bone therapy agents.
  • To introduce emerging agents for future clinical use.
  • To outline the characteristics and applications of these radiopharmaceuticals.

Main Methods:

  • Literature review of commercially available and investigational radionuclide bone therapy agents.
  • Comparison of radiopharmaceutical properties, including uptake, dosimetry, and efficacy.

Related Experiment Videos

  • Analysis of current clinical applications and potential future roles.

    • Main Results:

    • Several radiopharmaceuticals are approved for palliative treatment of painful bone metastases.
    • Emerging agents show promise for improved efficacy and broader applications.
    • Desirable characteristics include high bone uptake, rapid clearance from normal tissues, and targeted delivery to metastatic sites.

    Conclusions:

    • Radionuclide bone therapy is an established treatment for painful bone metastases.
    • Ongoing research aims to expand the utility of these agents, potentially including adjuvant roles.
    • Understanding agent characteristics is crucial for effective clinical application.